Current Report Filing (8-k)
November 01 2021 - 6:12AM
Edgar (US Regulatory)
0001213660
false
CN
0001213660
2021-10-28
2021-10-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 28, 2021
BIMI International Medical Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-34890
|
|
02-0563302
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
9th
Floor, Building 2,
Chongqing Corporation Avenue,
Yuzhong District, Chongqing, P. R. China
|
|
116000
|
(Address
of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (8604) 1182209211
Not Applicable
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common stock,
$0.001 par value
|
|
BIMI
|
|
The Nasdaq
Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
October 28, 2021 BIMI International Medical Inc. (the “Company”) renewed the term of employment of the Company’s CEO
Mr. Tiewei Song for one year and entered into a new employment agreement (the “Renewed Executive Employment Agreement”),
effective October 1, 2021. Under the Renewed Executive Employment Agreement, Mr. Tiewei Song’s compensation shall consist of an
annual base salary of $1,000,000 in cash and an annual stock compensation of 1 million shares of the Company’s common stock. Other
terms of the Renewed Executive Employment Agreement are substantially similar to the two-year executive employment agreement entered
into by the Company and Mr. Song on October 1, 2019.
The
Renewed Executive Employment Agreement is filed herewith as Exhibit 10.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: November 1, 2021
|
BIMI International
Medical Inc.
|
|
|
|
By:
|
/s/
Tiewei Song
|
|
Name:
|
Tiewei Song
|
|
Title:
|
Chief Executive Officer
|
2
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Sep 2023 to Sep 2024